Tirzepatide and semaglutide are often compared because both are used in FDA-approved metabolic medicines. Their biology is not identical: semaglutide targets the GLP-1 receptor, while tirzepatide targets both GIP and GLP-1 receptors.
GLP-1 receptor activation influences glucose-dependent insulin secretion, glucagon signaling, appetite and gastric emptying. Tirzepatide adds GIP-receptor activity. Researchers continue to investigate how the combined receptor profile contributes to observed metabolic outcomes.
SURMOUNT-5 directly compared maximum tolerated doses of tirzepatide and semaglutide over 72 weeks in adults with obesity but without type 2 diabetes. Mean weight change was greater in the tirzepatide group, and gastrointestinal events were the most common adverse events in both groups.
That result should not be converted into a universal promise. The trial used defined products, eligibility criteria, treatment protocols and clinical monitoring. It does not establish that unapproved or research-use versions produce the same outcomes.
“Better” depends on the approved indication, medical history, contraindications, tolerability, availability and clinician judgment. A head-to-head population average cannot choose treatment for an individual.
It includes GLP-1 receptor activity but is more precisely described as a dual GIP/GLP-1 receptor agonist.
No. Trial results are group averages and individual outcomes vary.
FDA-approved Zepbound labeling does not recommend coadministration with another tirzepatide product or any GLP-1 receptor agonist.
Explore GenLab Meds Research Materials
Compare molecule-specific research documentation in the GenLab Meds catalog. Research use only.
SURMOUNT-5 trial: SURMOUNT-5 head-to-head trial FDA-approved labeling: FDA-approved Zepbound labeling
Educational content only. This article does not provide medical advice, dosing or treatment instructions. Research products are for laboratory use only—not for human or veterinary use.
